Page last updated: 2024-11-02

phenobarbital and Myelodysplastic Syndromes

phenobarbital has been researched along with Myelodysplastic Syndromes in 1 studies

Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.

Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Peyrl, A1
Weichert, N1
Kühl, JS1
Ebell, W1
Hernáiz Driever, P1

Other Studies

1 other study available for phenobarbital and Myelodysplastic Syndromes

ArticleYear
Levetiracetam as a possible cause of secondary graft failure after allogenic hematopoietic stem cell transplantation.
    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 2015, Volume: 19, Issue:1

    Topics: Adolescent; Anticonvulsants; Blood Cell Count; Graft Rejection; Hematopoietic Stem Cell Transplantat

2015